Ascletis Pharma (HKSE:01672) Repurchase of Stock : HK$-105.57 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Repurchase of Stock?

Ascletis Pharma's Repurchase of Stock for the six months ended in Dec. 2024 was HK$-60.54 Mil.

Ascletis Pharma's Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-105.57 Mil.

Ascletis Pharma Repurchase of Stock Historical Data

The historical data trend for Ascletis Pharma's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Repurchase of Stock Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Repurchase of Stock

Get a 7-Day Free Trial

-23.24

-35.13

-86.37

-105.20

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Repurchase of Stock	Get a 7-Day Free Trial												-	-10.99	-75.38	-45.03	-60.54

Ascletis Pharma Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-105.57 Mil.

Ascletis Pharma Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Repurchase of Stock

Comparable Companies

Traded in Other Exchanges

ASCLF:USA 2VJ:Germany

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.

Executives

Wu Jinzi Jason	2101 Beneficial owner
Wu Judy Hejingdao	2101 Beneficial owner
Jjw12 Limited
Lakemont Holding Llc
Jjw11 Limited
C-bridge Capital Gp, Ltd.	2201 Interest of corporation controlled by you
Fu Wei	2201 Interest of corporation controlled by you
Tf Capital Ii Ltd.	2201 Interest of corporation controlled by you
Tf Capital, Ltd.	2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited	2201 Interest of corporation controlled by you
Yang Dan	2201 Interest of corporation controlled by you

Ascletis Pharma Headlines

No Headlines